Interpreting Phase 3 Trial Evidence in Metastatic Castration Sensitive Prostate Cancer (mCSPC)

In this segment, Dr. Charles J. Ryan asks Dr. Murilo De Almeida Luz to discuss how clinicians interpret data from pivotal phase 3 clinical trials evaluating androgen receptor pathway inhibitors used in combination therapy for metastatic castration sensitive prostate cancer (mCSPC). Dr. Luz reviews how randomized trials have demonstrated significant improvements in overall survival when androgen receptor pathway inhibitors are added to androgen deprivation therapy in the hormone sensitive setting. He notes that these studies have played a central role in establishing treatment intensification as a standard approach for many patients with mCSPC. The discussion also highlights the importance of evaluating safety outcomes alongside efficacy results, particularly because patients may remain on treatment for prolonged periods. Dr. Luz emphasizes that clinicians must carefully consider both survival benefits and tolerability profiles when applying trial findings to real world practice. This segment reinforces how interpretation of clinical trial evidence informs modern therapeutic strategies in metastatic castration sensitive prostate cancer.